These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

377 related items for PubMed ID: 28590525

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Are we underestimating the clinical efficacy of botulinum toxin (type A)? Quantifying changes in spasticity, strength and upper limb function after injections of Botox to the elbow flexors in a unilateral stroke population.
    Pandyan AD, Vuadens P, van Wijck FM, Stark S, Johnson GR, Barnes MP.
    Clin Rehabil; 2002 Sep; 16(6):654-60. PubMed ID: 12392341
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of abobotulinumtoxinA in spastic lower limb: Randomized trial and extension.
    Gracies JM, Esquenazi A, Brashear A, Banach M, Kocer S, Jech R, Khatkova S, Benetin J, Vecchio M, McAllister P, Ilkowski J, Ochudlo S, Catus F, Grandoulier AS, Vilain C, Picaut P, International AbobotulinumtoxinA Adult Lower Limb Spasticity Study Group.
    Neurology; 2017 Nov 28; 89(22):2245-2253. PubMed ID: 29093068
    [Abstract] [Full Text] [Related]

  • 10. Repeated treatments with botulinum toxin type a produce sustained decreases in the limitations associated with focal upper-limb poststroke spasticity for caregivers and patients.
    Elovic EP, Brashear A, Kaelin D, Liu J, Millis SR, Barron R, Turkel C.
    Arch Phys Med Rehabil; 2008 May 28; 89(5):799-806. PubMed ID: 18452724
    [Abstract] [Full Text] [Related]

  • 11. IncobotulinumtoxinA Efficacy and Safety in Adults with Upper-Limb Spasticity Following Stroke: Results from the Open-Label Extension Period of a Phase 3 Study.
    Marciniak C, Munin MC, Brashear A, Rubin BS, Patel AT, Slawek J, Hanschmann A, Hiersemenzel R, Elovic EP.
    Adv Ther; 2019 Jan 28; 36(1):187-199. PubMed ID: 30484117
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of NABOTA in post-stroke upper limb spasticity: a phase 3 multicenter, double-blinded, randomized controlled trial.
    Nam HS, Park YG, Paik NJ, Oh BM, Chun MH, Yang HE, Kim DH, Yi Y, Seo HG, Kim KD, Chang MC, Ryu JH, Lee SU.
    J Neurol Sci; 2015 Oct 15; 357(1-2):192-7. PubMed ID: 26233808
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of botulinum toxin A in upper limb function of hemiplegic patients.
    Rousseaux M, Kozlowski O, Froger J.
    J Neurol; 2002 Jan 15; 249(1):76-84. PubMed ID: 11954872
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after stroke.
    Bakheit AM, Thilmann AF, Ward AB, Poewe W, Wissel J, Muller J, Benecke R, Collin C, Muller F, Ward CD, Neumann C.
    Stroke; 2000 Oct 15; 31(10):2402-6. PubMed ID: 11022071
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Effectiveness of botulinum toxin A for upper and lower limb spasticity in children with cerebral palsy: a summary of evidence.
    Lukban MB, Rosales RL, Dressler D.
    J Neural Transm (Vienna); 2009 Mar 15; 116(3):319-31. PubMed ID: 19142573
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and Safety of MT10107 (Coretox) in Poststroke Upper Limb Spasticity Treatment: A Randomized, Double-Blind, Active Drug-Controlled, Multicenter, Phase III Clinical Trial.
    Lee J, Chun MH, Ko YJ, Lee SU, Kim DY, Paik NJ, Kwon BS, Park YG.
    Arch Phys Med Rehabil; 2020 Sep 15; 101(9):1485-1496. PubMed ID: 32497599
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.